The ability to concentrate urine was a critical step in evolutionary development, and 15 defects in urine concentration continue to plague humans. In order for kidneys to appropriately 16 regulate urinary water excretion, by varying the concentration and/or dilution of urine, there 17 needs to be integrative interaction of multiple proteins in multiple renal epithelial cells. Two 18 critical proteins in this process are AQP2 and UT-A1. In the manuscript that is the subject of 19 this editorial focus, Dr. Klein and colleagues identify a new and novel mechanism regulating 20 both AQP2 and UT-A1. Specifically, they identify that the adenosine monophosphate (AMP)-21 stimulated kinase (AMPK) phosphorylates both of these proteins, a critical step necessary for 22 activation of their transport function. In vitro assays, using pharmacologic agonists of AMPK, 23 confirmed increased water and urea transport. 
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Introduction 35
The ability to excrete a concentrated urine was a critical future in evolutionary 36 development, and continues to be necessary for humans to maintain health. Urine concentration 37 is a complex process, and requires interaction between multiple renal epithelial cell segments and 38 the appropriate function of multiple proteins. Critical aspects of the roles of the thin descending 39 and thick ascending limb of the loop of Henle, the connecting segment and the collecting duct 40 had been recognized and intensively studies over the past several decades. The inability to 41 concentrate the urine appropriately is termed diabetes insipidus, and when it is due to kidney-42 specific defects it is termed nephrogenic diabetes insipidus (NDI) (1). 43
The recent study by Klein and colleagues in this issue (5) is an important addition to our 44 understanding of the molecular mechanisms regulating urine concentration and has the potential 45 for rapid clinical translation. Metformin is a medication widely used in clinical medicine for its 46 glucose lowering effects in patients with diabetes, and is believed to work by activating the 47 adenosine monophosphate-activated kinase, AMPK. Klein and colleagues show that AMPK is 48 present in the renal inner medulla and that it phosphorylates two key proteins involved in urine 49 concentration, AQP2 and UT-A1. In vitro microperfusion studies show that the AMPK agonist, 50 metformin, increases IMCD water and urea permeability, and that an alternative AMPK agonist, 51 AICAR, has similar effects on urea permeability. Finally, they show that in a model of 52 nephrogenic diabetes insipidus, genetic deletion of the V2 receptor, that metformin increases 53 urine concentration. 54
The molecular mechanisms through which metformin is having these effects is likely to 55 involve activation of the cytosolic energy sensor, AMPK. AMPK is a heterotrimeric protein,composed of one alpha subunit, one beta subunit and one gamma subunit (2), and Klein and 57 colleagues show that both known alpha subunits, alpha-1 and alpha-2, are expressed in the inner 58 medulla (5). AMPK is activated by AMP and ADP binding to the beta-subunit, and inhibited by 59 ATP, thereby enabling it to function as a "cytosolic energy sensor." However, AMPK is also 60 regulated by a variety of other mechanisms, including intracellular Ca +2 , liver kinase B (LKB), 61 calcium-calmodulin-dependent kinase kinase (CaMKKβ) and transforming growth factor β-62 activated kinase (TAK1) (2). Although metformin is widely recognized to activate AMPK, its 63 effects also include AMPK-independent mechanisms, including interaction with mTOR, 64 PRAS40 and RAPTOR (7). Klein and colleagues do show the alternative AMPK activator, 65 AICAR, has similar effects as metformin on IMCD urea permeability, supporting the likelihood 66 that metformin is active through AMPK. However, it is important to recognize that metformin 67 and AICAR can have similar biological effects, but through distinct, but differing, mechanisms 68 that do not involve AMPK (7). 69
The studies add to a growing list of evidence that AMPK has important biological roles 70 other than serving solely serving as a cytosolic "energy sensor." AMPK is been shown to 71 regulate multiple and transport processes in the kidney, including H-ATPase, NaPi2a, ROMK, 72
ENaC and KCNQ1 (8). It may be involved in the progression of chronic kidney disease, in renal 73 cystogenesis in autosomal dominant polycystic kidney disease and in acute kidney injury (3, 6, 74 9). Finally, it may be involved in renal cytokine responses (4). Of important concern, 75 particularly as clinical implications of AMPK activation are examined, is the report that AMPK 76 activation increases renal medullary cell apoptosis in both normally hydrated and dehydrated 77 mice with type II diabetes mellitus (10).
